Pfizer and partner BioNTech’s experimental injection meets expectations on agency guidance and is enough to initiate an agency review, according to staff of the U.S. Food and Drug Administration.
Pfizer and partner BioNTech’s experimental injection meets expectations on agency guidance and is enough to initiate an agency review, according to staff of the U.S. Food and Drug Administration.
